OptimizeRx OPRX Q2 2026 earnings

“Second quarter revenue and adjusted EBITDA both exceeded consensus expectations, reflecting continued margin expansion, disciplined execution, and resilience in our operating model. While year-over-year revenue declined and contracted revenue remains below prior-year levels, these trends are concentrated among a small number of customers, and we are encouraged by increased investment across other portions of our customer base. Our continued investment in platform capabilities, including recent product launches and expanded programmatic initiatives, is strengthening customer engagement as we move into the 2027 planning cycle. Despite some variability in second-half timing and mix, our first-half performance and commercial momentum give us confidence to reiterate full-year 2026 guidance of $95 million to $100 million in revenue and $21 million to $25 million in adjusted EBITDA. We also expanded the long-term opportunity for OptimizeRx through three platform advancements: DeepIntent became the first healthcare demand-side platform (DSP) to integrate our authenticated electronic health record (EHR) network, we launched our patent-pending Natural Language Audience Builder, and we introduced CopayCue, our next-generation copay activation solution. These innovations strengthen our position in artificial intelligence (AI)-enabled audience intelligence, programmatic point-of-care activation, and clinical workflow engagement while creating opportunities for recurring growth.”